<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="791">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04404244</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU P25a/ 2020</org_study_id>
    <nct_id>NCT04404244</nct_id>
  </id_info>
  <brief_title>Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic</brief_title>
  <acronym>PedCan-COVID</acronym>
  <official_title>Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatma Soliman Elsayed Ebeid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective follow-up non-intervention study that will be carried out at&#xD;
      Hematology/ Oncology Department, Children's hospital, Ain-Shams University, Cairo, Egypt. All&#xD;
      followed-up children below 18 years with cancer during the one year study period from May&#xD;
      2020 till Apr 2021 either at the out-patients clinic or inpatient department will be&#xD;
      recruited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:&#xD;
&#xD;
      On admission or during the outpatient visit:&#xD;
&#xD;
        1. Obtaining an informed consent .&#xD;
&#xD;
        2. Full medical history, concurrent medications, demographic data and epidemiological data&#xD;
           (history of contact to a COVID-19 case, history of travel), will be obtained.&#xD;
&#xD;
        3. A thorough physical examination will be performed.&#xD;
&#xD;
        4. Body weight, height, BMI, vital signs (blood pressure, heart rate and temperature) and&#xD;
           blood oxygen saturation) will be recorded.&#xD;
&#xD;
        5. Laboratory to perform the following tests:&#xD;
&#xD;
      Complete blood count with differential counts, COVID -19 reverse Transcription Polymerase&#xD;
      Chain Reaction (RT-PCR) test by nasopharyngeal swab.&#xD;
&#xD;
      During admission:&#xD;
&#xD;
      Whenever unexplained fever and or respiratory symptoms developed or whenever COVID19&#xD;
      suspected to have the following to be performed:&#xD;
&#xD;
        1. Symptom developed that necessitates to repeat oropharyngeal and nasopharyngeal swab if&#xD;
           indicated will be collected&#xD;
&#xD;
        2. Chest X-ray or CT chest will be recorded.&#xD;
&#xD;
        3. Laboratory to perform the following tests:&#xD;
&#xD;
      Complete blood count with differential counts,&#xD;
&#xD;
      COVID-19 RT-PCR test by oropharyngeal and nasopharyngeal swab:&#xD;
&#xD;
      C-reactive protein and serum ferritin level. Coagulation test; D. dimer, prothrombin time and&#xD;
      INR. Routine bacteriological study, blood culture and other symptoms/signs based cultures&#xD;
      will be recorded&#xD;
&#xD;
      On discharge:&#xD;
&#xD;
        -  Date of discharge&#xD;
&#xD;
        -  Period of admission&#xD;
&#xD;
        -  Period of fever&#xD;
&#xD;
        -  A thorough physical examination will be performed&#xD;
&#xD;
        -  Record the outcome&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of COVID-19 among children with cancer</measure>
    <time_frame>12 months</time_frame>
    <description>Measure the incidence of COVID-19 infection among children with cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Families training</measure>
    <time_frame>12 months</time_frame>
    <description>Families training about adhering to standard precautions for basic and respiratory hygiene to reduce the risk of transmission</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronavirus COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All followed-up children below 18 years with with malignancy either hematological or solid&#xD;
        tumors or hematological condition during the one year study period from May 2020 till Apr&#xD;
        2021 either at the out-patients clinic or inpatient department will be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children below 18 years with malignancy either hematological or solid tumors or&#xD;
&#xD;
          2. Children below 18 years with hematological condition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients or care-givers refusal to be enrolled in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatma Ebeid</last_name>
    <role>Principal Investigator</role>
    <affiliation>Excuitive Director of MARSI-CRC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatma Ebeid</last_name>
    <phone>+201095569596</phone>
    <email>dr.fatma_ebeid@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center</name>
      <address>
        <city>Cairo</city>
        <state>Non-US</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatma Soliman E Ebeid</last_name>
      <phone>01095569596</phone>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Fatma Soliman Elsayed Ebeid</investigator_full_name>
    <investigator_title>Executive Director of Faculty of Medicine Ain Shams University Research Institute - Clinical Research Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

